Soliris®


 
 
 
 
 
 
 
 
 


 

Soliris® (Eculizumab) is a monoclonal antibody in the category of immunosuppressive drugs used for the treatment of hemolytic blood disorders. SOLIRIS® works by selectively slowing down the complement system in the human body.

Soliris® is manufactured by Alexion.

Administration and Dosage:

Recommended administration of SOLIRIS® is an intravenous infusion weekly for 4 weeks following by the 5th dose 1 week later and then every 2 weeks thereafter.

Common Side Effects:

The more common side effects of SOLIRIS® include serious allergic reactions.

More Information:

Please read the full Prescribing Information for SOLIRIS® and discuss any questions you have with your doctor.

Ready to Schedule an Appointment?

Please CLICK HERE to get started.

Indication:

Soliris® is indicated to treat:

  • Paroxysmal Nocturnal Hemoglobinuria
  • Atypical Hemolytic Uremic Syndrome
  • Generalized Myasthenia Gravis
  • Neuromyelitis Optica Spectrum Disorder